Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 66 entries
View as:

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

Phase: N/A Priority: Normal
NCT ID: NCT03869892 Org: User:
Start: 03/21/19 End: 12/31/25 Due: 12/31/26

SPARK-ALL: Calaspargase Pegol in Adults with ALL

Phase: N/A Priority: Normal
NCT ID: NCT04817761 Org: User:
Start: 07/07/21 End: 02/09/26 Due: 02/09/27

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01283945 Org: User:
Start: 07/31/10 End: 05/04/17 Due: 05/04/18

Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)

Phase: N/A Priority: Normal
NCT ID: NCT01965145 Org: User:
Start: 11/30/12 End: 09/30/15 Due: 09/30/16

Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT02446990 Org: User:
Start: 09/30/09 End: 01/31/14 Due: 01/31/15

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04742101 Org: User:
Start: 03/10/21 End: 12/30/25 Due: 12/30/26

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

Phase: N/A Priority: Normal
NCT ID: NCT05312372 Org: User:
Start: 05/31/25 End: 06/30/26 Due: 06/30/27

Post Marketing Surveillance Study for ONIVYDE® in South Korea

Phase: N/A Priority: Normal
NCT ID: NCT03446872 Org: User:
Start: 03/08/18 End: 08/29/20 Due: 08/29/21

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03755154 Org: User:
Start: 07/17/19 End: 11/06/23 Due: 11/06/24

A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19

Phase: N/A Priority: Normal
NCT ID: NCT02735083 Org: User:
Start: 03/10/21 End: 09/30/28 Due: 09/30/29

S90652 in Paediatric Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00202553 Org: User:
Start: 07/31/03 End: 12/31/06 Due: 12/31/07

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Phase: N/A Priority: Normal
NCT ID: NCT05484622 Org: User:
Start: 01/20/23 End: 08/30/27 Due: 08/30/28

Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02481154 Org: User:
Start: 06/30/15 End: 06/19/24 Due: 06/19/25

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02632708 Org: User:
Start: 12/31/15 End: 07/24/26 Due: 07/24/27

Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

Phase: N/A Priority: Normal
NCT ID: NCT03672695 Org: User:
Start: 11/28/18 End: 05/30/23 Due: 05/30/24

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Phase: N/A Priority: Normal
NCT ID: NCT04164901 Org: User:
Start: 01/05/20 End: 05/31/28 Due: 05/31/29

Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study

Phase: N/A Priority: Normal
NCT ID: NCT02441218 Org: User:
Start: 09/30/06 End: 04/30/10 Due: 04/30/11

Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms

Phase: N/A Priority: Normal
NCT ID: NCT02626572 Org: User:
Start: 02/28/15 End: 09/30/17 Due: 09/30/18

Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT04744636 Org: User:
Start: 04/03/17 End: 09/15/18 Due: 09/15/19

Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT00202579 Org: User:
Start: 09/30/04 End: 02/28/06 Due: 02/28/07

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05223673 Org: User:
Start: 04/21/22 End: 06/21/23 Due: 06/21/24

Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients

Phase: N/A Priority: Normal
NCT ID: NCT04605978 Org: User:
Start: 08/03/21 End: 05/09/23 Due: 05/09/24

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT05674474 Org: User:
Start: 03/14/23 End: 07/18/23 Due: 07/18/24

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02920697 Org: User:
Start: 03/31/14 End: 10/22/18 Due: 10/22/19

Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event

Phase: N/A Priority: Normal
NCT ID: NCT02877615 Org: User:
Start: 12/19/16 End: 03/10/19 Due: 03/10/20